Psychiatrist Sleep Medication Guide: Prescription Drugs, Peptides, and Supplements

Sleep problems are one of the most common reasons patients come to a psychiatrist. Not because they tried a supplement and it failed, though many have. Finding the right psychiatrist sleep medication, peptide, or supplement is rarely about picking one item off a list. The question is rarely “what should I take to sleep.” The question is what is actually driving the problem, and which intervention matches the driver.

DSIP and Epitalon, both sometimes pitched for sleep, went before an FDA advisory committee in July 2026. I graded their actual evidence in the peptide vote analysis.

Some sleep peptides have a more interesting evidence base than their reputation suggests, and less than their marketing claims. DSIP is one, broken down in my guide to the DSIP peptide.

This article is a psychiatrist’s walk-through of the full landscape of sleep interventions: prescription medications, peptides, and supplements. Not a ranking. Not a “top 10 best sleep aids” listicle. A clinical framework for understanding what each category does, what the evidence actually supports, where the gaps are, and how a psychiatrist thinks about choosing between them for a specific patient. Some of what follows will confirm what you have read elsewhere. Some of it will contradict popular advice. The goal is accuracy, not reassurance.

---

When Sleep Problems Need More Than Sleep Hygiene

Sleep hygiene matters. Consistent wake time, dark room, no screens before bed, no caffeine after noon. These interventions are real, free, and effective for many people. Cognitive behavioral therapy for insomnia (CBT-I) is the gold standard first-line treatment for chronic insomnia and outperforms medication in long-term studies. None of that is in dispute.

The patients who end up in a psychiatrist’s office for sleep have usually tried these things. They have tried melatonin from the drugstore. They have tried chamomile tea. They have listened to the podcasts. The sleep problem persists because something else is going on: an anxiety disorder that activates at night, a depression that fragments sleep architecture, a medication that disrupts REM, a hormonal shift that changes sleep quality, or a pattern of chronic hyperarousal that no amount of lavender spray is going to fix.

Identifying the driver changes the treatment. An SSRI that resolves anxiety may fix the insomnia without ever prescribing a sleep medication. Adjusting a stimulant dose or timing may eliminate the sleep-onset problem. Treating low testosterone in a man with fatigue, low mood, and poor sleep may improve all three without adding a sedative. The interventions described below are tools. The evaluation determines which tool fits.

---

Prescription Medications for Sleep

Prescription sleep medications are not one category. They are several distinct categories with different mechanisms, different risk profiles, and different clinical roles. A psychiatrist choosing a sleep medication is not picking from a menu. They are matching a mechanism to a clinical picture. The categories below are organized by how a psychiatrist typically thinks about them in practice, starting with the options most commonly used for chronic insomnia and ending with the options that are appropriate only in specific, limited contexts.

Trazodone

Trazodone is a serotonin antagonist and reuptake inhibitor originally developed as an antidepressant. At antidepressant doses (150 to 600 milligrams), it is rarely used for that purpose today because better-tolerated options exist. At low doses (25 to 100 milligrams), it is one of the most commonly prescribed off-label sleep aids in psychiatry. The sedation comes primarily from its antagonism of histamine H1 receptors and serotonin 5-HT2A receptors at low doses.

Trazodone is not FDA-approved for insomnia, but its off-label use for sleep is widespread and well-studied. It does not carry the dependency risk of benzodiazepines or Z-drugs. It does not suppress REM sleep. It can cause morning grogginess at higher doses, orthostatic hypotension, and in rare cases priapism in men. For patients with comorbid depression or anxiety, trazodone can serve double duty, modest antidepressant effect alongside the sleep benefit, though at the low sleep doses, the antidepressant effect is minimal.

Mirtazapine

Mirtazapine is a noradrenergic and specific serotonergic antidepressant (NaSSA) with potent antihistamine effects at lower doses. At 7.5 to 15 milligrams, it is strongly sedating. At higher doses (30 to 45 milligrams), the noradrenergic effects partially counterbalance the sedation. This makes mirtazapine paradoxically more sedating at lower doses than higher ones.

Mirtazapine is particularly useful when insomnia co-occurs with depression, anxiety, poor appetite, or unintentional weight loss. The appetite-stimulating effect is clinically significant; patients on mirtazapine almost universally report increased appetite and often gain weight. For underweight patients with comorbid depression and insomnia, this side effect profile is a feature rather than a bug. For patients concerned about weight gain, mirtazapine is a harder sell. The sedation tends to diminish over the first few weeks of use, though many patients report persistent benefit for sleep onset.

Low-Dose Doxepin

Doxepin is a tricyclic antidepressant that, at very low doses (3 to 6 milligrams, marketed as Silenor), is FDA-approved for the treatment of insomnia characterized by difficulty with sleep maintenance. At these doses, doxepin acts almost purely as a histamine H1 antagonist. The antidepressant and anticholinergic effects that make full-dose tricyclics problematic are not clinically significant at the 3 to 6 milligram insomnia dose.

Low-dose doxepin is one of the few prescription sleep medications with a clean side-effect profile at its labeled dose for insomnia. It does not cause dependency. It does not impair next-morning psychomotor performance in most studies. It is particularly useful for patients who fall asleep without difficulty but wake in the middle of the night or too early in the morning and cannot return to sleep. Its role is narrower than trazodone’s, but for the right clinical picture, it works well.

Hydroxyzine

Hydroxyzine is a first-generation antihistamine with anxiolytic properties. It is FDA-approved for anxiety and as a preoperative sedative, not specifically for insomnia, but it is widely used off-label for sleep, particularly in patients with comorbid anxiety. Doses for sleep range from 25 to 50 milligrams at bedtime. It works through histamine H1 antagonism and has some serotonin 5-HT2A effects.

The advantages of hydroxyzine for sleep are its lack of dependency potential, its anxiolytic effects, and its low cost. The disadvantages are next-morning sedation (it has a relatively long half-life of about 20 hours in adults), anticholinergic effects at higher doses, and the possibility of QTc prolongation at higher doses. For patients who need something for both nighttime anxiety and sleep onset, hydroxyzine occupies a useful niche.

Gabapentin

Gabapentin is an anticonvulsant that modulates calcium channels and enhances slow-wave sleep. It is not FDA-approved for insomnia, but off-label use for sleep is common, particularly in patients with comorbid neuropathic pain, restless legs syndrome, or alcohol use disorder. Doses for sleep typically range from 100 to 600 milligrams at bedtime.

Gabapentin’s sleep benefit comes partly from its ability to increase slow-wave sleep (stage N3), which is the deepest and most restorative phase. This distinguishes it from many other sleep medications, which tend to increase lighter stages of sleep. The clinical situations where gabapentin shines for sleep are those involving pain, nerve-related discomfort, or restless legs alongside insomnia. Prescribers should be aware that gabapentin has acquired some abuse potential in certain populations and some states have reclassified it as a scheduled substance.

Dual Orexin Receptor Antagonists (DORAs)

This is the newest class of prescription sleep medication and represents a genuinely different mechanism from everything else on this list. The orexin system is a wake-promoting pathway in the brain. Orexin neuropeptides (also called hypocretins) maintain arousal by acting on OX1 and OX2 receptors. DORAs work by blocking these receptors, effectively turning down the wake signal rather than amplifying a sedation signal. This is a fundamentally different approach from GABAergic medications like benzodiazepines and Z-drugs.

Three DORAs are currently FDA-approved for insomnia: suvorexant (Belsomra), lemborexant (Dayvigo), and daridorexant (Quviviq). All three improve sleep onset and sleep maintenance in clinical trials. Their side-effect profiles are favorable compared to older sleep medications. No respiratory depression, minimal abuse potential, no rebound insomnia in most studies, and they preserve natural sleep architecture rather than distorting it.

The most common side effects are next-morning drowsiness and, in some patients, unusual dreams or sleep paralysis, which makes sense given the relationship between the orexin system and REM sleep regulation. Suvorexant was approved in 2014, lemborexant in 2019, and daridorexant in 2022. Network meta-analyses suggest daridorexant may have a slight edge in subjective total sleep time, but head-to-head trials are limited and individual response varies. For patients who want an FDA-approved sleep medication without the dependency risk of benzodiazepines, DORAs are the most important development in sleep pharmacology in the last decade.

Ramelteon

Ramelteon is a melatonin receptor agonist (MT1 and MT2) that is FDA-approved for insomnia characterized by difficulty with sleep onset. Unlike exogenous melatonin supplements, ramelteon is a prescription medication with a defined pharmacokinetic profile and consistent dosing. It works by mimicking the circadian signal that tells the brain it is time to sleep.

Ramelteon has no abuse potential (it is unscheduled), no next-morning psychomotor impairment in most studies, and no dependency risk. Its limitation is that the effect size is modest. It improves sleep onset latency by roughly 10 to 20 minutes on average in clinical trials, which is clinically meaningful for some patients and disappointing for others. It does not significantly improve sleep maintenance. For patients with circadian rhythm disruption or jet lag-type sleep-onset difficulty, ramelteon can be effective. For patients with severe, multifactorial insomnia, it is usually not sufficient as monotherapy.

Z-Drugs: Zolpidem and Eszopiclone

Zolpidem (Ambien) and eszopiclone (Lunesta) are non-benzodiazepine GABA-A receptor agonists that act selectively on the alpha-1 subunit of the GABA-A receptor. They produce sedation without the broad anxiolytic, muscle relaxant, and anticonvulsant effects of benzodiazepines. Both are FDA-approved for insomnia and are effective for sleep onset and, in extended-release formulations, for sleep maintenance.

Z-drugs are not first-line for chronic insomnia in current guidelines. Their issues are well-documented: tolerance can develop with nightly use, there is dependency potential with prolonged use, rebound insomnia can occur on discontinuation, and complex sleep-related behaviors (sleepwalking, sleep-driving, sleep-eating) have been reported, particularly with zolpidem. The FDA has progressively tightened labeling on these medications. They remain useful for short-term use, situational insomnia (travel, acute stressors), and as short-term bridges while longer-term treatments take effect. They should not be the default chronic insomnia medication when better-tolerated alternatives exist.

Benzodiazepines

Benzodiazepines (lorazepam, clonazepam, temazepam, and others) act on GABA-A receptors and produce sedation, anxiolysis, and muscle relaxation. They are effective for acute insomnia but are not recommended as first-line treatment for chronic insomnia by any current evidence-based guideline. Chronic use carries risks of tolerance, physiologic dependence, cognitive impairment, and increased fall risk, particularly in older adults.

Benzodiazepines have a legitimate role in acute situational anxiety, specific anxiety disorders, and very short-term insomnia management. They do not have a legitimate role as a nightly chronic sleep medication for most patients. A psychiatrist who prescribes a benzodiazepine for sleep should be doing so with a specific clinical rationale, a defined duration, and a plan for tapering. Indefinite nightly benzodiazepine use for insomnia is not consistent with current standards of care.

---

---

Peptides for Sleep

Peptide therapy for sleep is a newer and less well-studied area than prescription pharmacology. The evidence base for most sleep-related peptides consists of small studies, preclinical data, and Russian-language literature that has not been replicated in large Western trials. This does not mean peptides are ineffective. It means the evidence is early, and anyone prescribing peptides for sleep should be transparent about that. A psychiatrist’s role in this space is to apply the same standard of clinical judgment to peptides that would be applied to any other intervention: what is the mechanism, what does the evidence show, what are the risks, and is this the right intervention for this patient.

Delta Sleep-Inducing Peptide (DSIP)

DSIP is a nine-amino-acid neuropeptide first isolated in 1974 from the cerebral venous blood of rabbits in an induced state of sleep. It was initially believed to be a primary endogenous sleep factor, though subsequent research has produced mixed results. Several small clinical trials in chronic insomniacs have shown improvement in sleep efficiency, total sleep time, and number of nocturnal awakenings with DSIP administration. A 1987 placebo-controlled trial by Schneider-Helmert found that seven nights of DSIP administration substantially improved night sleep in 14 chronic insomniacs, with effects maintained for the first post-treatment night.

DSIP has been described as a sleep-promoting substance rather than a sedative, meaning it modulates the sleep-wake cycle rather than inducing pharmacological sedation. Its effects appear to be more pronounced in people with disturbed sleep than in healthy sleepers. The practical limitation is molecular instability. DSIP has a short half-life due to rapid enzymatic degradation, which creates delivery challenges. It is available from compounding pharmacies but is not FDA-approved and does not have the regulatory infrastructure that prescription medications carry. The evidence is intriguing but insufficient to consider DSIP a first-line sleep intervention.

Epitalon

Epitalon (also spelled Epithalon) is a synthetic tetrapeptide based on the natural peptide epithalamin, derived from the pineal gland. Its primary studied effects relate to telomerase activation and melatonin regulation. The sleep relevance comes through the melatonin pathway: epitalon has been shown in animal studies to stimulate melatonin production from the pineal gland, which could theoretically improve circadian rhythm regulation and sleep onset in individuals whose endogenous melatonin production has declined, particularly with aging.

The evidence for epitalon’s effects on sleep in humans is limited primarily to its effects on melatonin secretion patterns. The peptide is not FDA-approved and the clinical trial data is predominantly from Russian research groups. For patients interested in supporting endogenous melatonin production rather than taking exogenous melatonin, epitalon represents a theoretically sound but clinically unproven approach. It should be discussed as investigational.

Pinealon

Pinealon is a short-chain tripeptide (Glu-Asp-Arg) developed by the same Russian research group that developed epitalon (the St. Petersburg Institute of Bioregulation and Gerontology). It is classified as a bioregulator peptide targeting pineal gland function. Like epitalon, pinealon’s relevance to sleep comes through the melatonin regulation pathway, with the proposed mechanism being normalization of pineal gland activity and melatonin synthesis. Animal studies suggest it may have neuroprotective and antioxidant properties as well.

The evidence base for pinealon is even thinner than for epitalon. Most available studies are preclinical and published in Russian-language journals. Pinealon is available through peptide suppliers and compounding pharmacies but has no FDA approval and no large-scale clinical trial data for sleep in humans. It occupies an investigational category and should be framed accordingly. Patients interested in pinealon should understand that they are early adopters of a compound with a plausible but unproven mechanism.

CJC-1295 and Ipamorelin

CJC-1295 (a growth hormone-releasing hormone analog) and ipamorelin (a growth hormone secretagogue) are often used together to stimulate pulsatile growth hormone release. The sleep relevance is indirect: growth hormone is predominantly secreted during slow-wave sleep, and enhancing GH pulse amplitude may improve the quality of deep sleep. Patients on CJC-1295/ipamorelin protocols frequently report subjectively deeper, more restorative sleep as a secondary benefit.

The mechanism is plausible: there is a well-established bidirectional relationship between growth hormone secretion and slow-wave sleep. However, these peptides are not specifically sleep medications and should not be prescribed primarily for insomnia. Their sleep benefit is best understood as a side effect of their primary function. They are most relevant for patients who are using GH secretagogues for other reasons (body composition, recovery, anti-aging) and are experiencing sleep improvement as an additional benefit.

---

Supplements for Sleep

Supplements occupy a different evidence category than prescription medications. They are not FDA-regulated for efficacy. Quality control varies dramatically between manufacturers. Dosing in commercial products is frequently much higher than what clinical evidence supports. A psychiatrist’s role with supplements is to be honest about what the evidence does and does not show, and to help patients avoid the trap of assuming that “natural” means “effective” or “safe.”

Magnesium

Magnesium is involved in over 300 enzymatic reactions in the body, including GABA receptor function, melatonin synthesis, and cortisol regulation, all of which are relevant to sleep. Magnesium deficiency is common and is associated with poor sleep quality in observational studies. Supplementation in magnesium-deficient individuals consistently improves sleep outcomes.

The form of magnesium matters clinically. Magnesium glycinate is well-absorbed and less likely to cause gastrointestinal side effects than magnesium oxide or citrate. The glycine component may contribute additional sleep benefit (discussed below). Magnesium L-threonate (Magtein) has been specifically studied for brain bioavailability and was shown in a 2024 randomized placebo-controlled trial to improve insomnia severity scores, with continuing improvement at weeks two and three where placebo plateaued. Magnesium oxide, the cheapest and most common form in retail supplements, has poor bioavailability and is primarily useful as a laxative, not a sleep aid.

Typical effective doses for sleep are 200 to 400 milligrams of elemental magnesium from glycinate or threonate forms, taken 30 to 60 minutes before bed. The evidence is strongest in older adults and in individuals with documented or likely magnesium deficiency. In young, well-nourished adults with adequate dietary magnesium, supplementation may offer less benefit.

L-Theanine

L-theanine is a non-protein amino acid found primarily in tea leaves. It promotes relaxation without sedation by increasing alpha brain wave activity and modulating GABA, serotonin, and dopamine. The effects on sleep are primarily indirect: L-theanine reduces anxiety and mental hyperactivity, which makes sleep onset easier for patients whose insomnia is driven by a racing mind rather than a biological clock problem.

Clinical trials have shown that 200 to 400 milligrams of L-theanine taken before bed can reduce stress markers and improve subjective sleep quality, though the effects on objective polysomnographic measures are modest. L-theanine is well-tolerated, has no known dependency potential, and does not cause next-morning sedation. Its best role is as part of a broader sleep-support strategy rather than as a standalone insomnia treatment. For patients on anxiolytic peptides like Selank, the mechanism is complementary rather than redundant; L-theanine works through different receptor pathways.

Apigenin

Apigenin is a flavonoid found in chamomile, celery, and parsley that acts as a positive allosteric modulator of GABA-A receptors, producing mild anxiolytic and sedative effects. Most of the clinical evidence for apigenin’s sleep benefits comes from studies using chamomile extract rather than isolated apigenin. A 2017 randomized controlled trial found that chamomile extract improved sleep quality in elderly subjects compared to placebo.

The typical supplemental dose of isolated apigenin for sleep is 50 milligrams taken before bed, though this dose comes from popular recommendation rather than dose-finding clinical trials. Apigenin is well-tolerated and has no known dependency potential. Its effects are mild. It is best understood as a subtle calming agent that may contribute to sleep quality when combined with other interventions, not as a sleep medication replacement.

Glycine

Glycine is an inhibitory amino acid neurotransmitter involved in thermoregulation, NMDA receptor modulation, and sleep architecture. Three grams of glycine taken before bed has been shown in controlled studies to improve subjective sleep quality, reduce sleep-onset latency, and decrease daytime sleepiness. The proposed mechanism involves glycine’s effect on peripheral vasodilation and core body temperature reduction, which signals sleep onset to the circadian system.

Glycine is also the amino acid conjugated to magnesium in magnesium glycinate, which means patients taking magnesium glycinate are getting a small amount of glycine alongside the magnesium. Standalone glycine supplementation at 3 grams is well-tolerated and inexpensive. The evidence base is small but consistent, and the biological mechanism is plausible and well-characterized. For patients who want an evidence-based, low-risk supplement for sleep, glycine is one of the more defensible options.

Melatonin

Melatonin is the endogenous hormone that signals darkness and sleep onset to the circadian system. Exogenous melatonin supplements are the most widely used over-the-counter sleep aid in the United States. The evidence supports its use for circadian rhythm disorders, jet lag, and delayed sleep-wake phase disorder. For primary insomnia in adults, the evidence is more modest. Meta-analyses show it reduces sleep-onset latency by about 7 to 12 minutes on average, which is real but small.

The most common mistake with melatonin is the dose. Commercial melatonin products typically contain 5 to 10 milligrams, and some contain 20 milligrams. The physiologic dose, the amount that produces blood levels similar to what the pineal gland naturally secretes, is 0.3 to 0.5 milligrams. Higher doses do not produce better sleep and can cause paradoxical effects including next-morning grogginess, vivid dreams, and desynchronization of the circadian signal. Timing matters as much as dose: melatonin should be taken 30 to 60 minutes before the desired sleep onset, not at midnight when sleep is already overdue. If you have ADHD, I cover low-dose melatonin timing and other sleep supplements in my guide to supplements for ADHD.

Inositol

Myo-inositol is a sugar alcohol involved in cell signaling, including serotonin and GABA receptor function. It has been studied primarily for anxiety, panic disorder, and OCD, with some evidence supporting its use in those conditions. The sleep relevance is secondary, by reducing anxiety and intrusive thoughts, inositol may improve sleep in patients whose insomnia is anxiety-driven.

Doses used in clinical trials for anxiety are high, typically 12 to 18 grams per day. At these doses, gastrointestinal side effects (nausea, diarrhea) are common. Inositol is not specifically a sleep compound and should not be positioned as one. It is most relevant for patients with comorbid anxiety or OCD where the mood benefit carries a secondary sleep improvement. It does not act directly on sleep architecture.

Valerian Root

Valerian root has a long history of traditional use as a sedative and sleep aid. The proposed mechanism involves modulation of GABA receptors through valerenic acid and other constituents. Despite its popularity, the clinical evidence for valerian root as a sleep aid is disappointing. A comprehensive 2025 narrative review in Nutrition Reviews concluded that valerian root extracts lack adequate evidence to support their use for sleep disorders. Multiple systematic reviews and meta-analyses have reached similar conclusions: the effect sizes are small, the studies are heterogeneous, and the results are inconsistent.

Valerian is generally well-tolerated and has a good safety profile, which may explain its enduring popularity despite weak evidence. Some patients report subjective benefit, which may reflect a genuine but modest effect that clinical trials are too blunt to detect, or may reflect placebo response. A psychiatrist should not discourage a patient who finds valerian helpful, but should also not recommend it as a primary sleep intervention when better-supported options exist.

Vitamin D

Vitamin D deficiency has been associated with poor sleep quality, shorter sleep duration, and increased risk of sleep disorders in multiple observational studies. The proposed mechanisms involve vitamin D receptors in brain regions that regulate sleep, as well as vitamin D’s role in serotonin synthesis (serotonin being the precursor to melatonin). Supplementation in deficient individuals has shown improvement in sleep quality in some but not all controlled trials.

Vitamin D is not a sleep supplement in the traditional sense. It is a nutrient that, when deficient, can contribute to poor sleep among many other problems. Checking a vitamin D level and correcting deficiency is part of a thorough sleep workup, not because vitamin D is a sleep medication but because deficiency is common and correctable. Standard supplementation doses range from 1,000 to 5,000 IU daily depending on the severity of deficiency. Taking vitamin D in the morning rather than at night is generally recommended, as some patients report that evening dosing can paradoxically disrupt sleep.

Omega-3 Fatty Acids

Omega-3 fatty acids (EPA and DHA) have been studied for a wide range of neuropsychiatric outcomes, including sleep. Several observational studies have found associations between higher omega-3 intake and better sleep quality, and a few controlled trials have shown modest improvements in sleep parameters with supplementation. The mechanisms may involve omega-3’s role in serotonin metabolism, neuroinflammation reduction, and cell membrane fluidity in sleep-regulating neurons.

The evidence is not strong enough to recommend omega-3 supplementation specifically for insomnia. It is strong enough to recommend adequate omega-3 intake as part of general brain health, with sleep quality as one of several potential benefits. For patients already taking omega-3 for mood support (which has a better evidence base, particularly for EPA in depression), any sleep benefit is an additional return on the same intervention. Typical doses for psychiatric purposes are 1 to 2 grams of combined EPA/DHA daily.

CBD (Cannabidiol)

CBD is the most commercially visible sleep supplement in the current market, and the gap between its marketing and its evidence base is substantial. CBD interacts with the endocannabinoid system, serotonin 5-HT1A receptors, and several other receptor targets. The primary evidence for CBD in the sleep context comes from anxiety studies, where reduced anxiety secondarily improved sleep. Direct evidence for CBD as a sleep aid is limited and inconsistent.

A commonly cited 2019 case series by Shannon and colleagues found that anxiety scores improved in 79 percent of participants and sleep scores improved in 67 percent in the first month, though the sleep improvement was not sustained for all participants over time. This was an open-label case series, not a randomized controlled trial, and the conclusions should be interpreted accordingly. Higher doses of CBD (above 160 milligrams) may have sedative properties, but lower doses (under 50 milligrams, which is what most commercial products contain) have not consistently demonstrated sleep effects in controlled settings.

CBD also has clinically significant drug interactions, particularly through CYP3A4 and CYP2C19 inhibition, which can affect the metabolism of psychiatric medications including certain SSRIs, benzodiazepines, and antipsychotics. Patients using CBD alongside prescription medications need to disclose this, and prescribers need to be aware of the interaction potential. The quality control issues in the commercial CBD market, inconsistent labeling, THC contamination, variable bioavailability, add another layer of concern. CBD may have a role in sleep management for some patients, but the current evidence does not support its widespread use as a primary sleep intervention.

---

When to Combine Approaches

The patients who benefit most from a psychiatrist’s involvement in sleep management are those whose sleep problems are multifactorial. A man with low testosterone, mild depression, and chronic insomnia may benefit from TRT, an antidepressant, and a targeted supplement stack simultaneously; not because any one of those is a magic bullet, but because each addresses a different piece of the picture. A woman in perimenopause with anxiety, hot flashes, and fragmented sleep may benefit from an SSRI for the anxiety, hormonal management for the hot flashes, and low-dose trazodone for the sleep, adjusted over time as each piece stabilizes.

The integrated model works when someone is coordinating it. Patients who are self-prescribing a peptide from one clinic, a supplement stack from a podcast, and a prescription from a primary care provider who does not know about the other two are getting fragmented care, not integrated care. Part of the value of seeing a psychiatrist for sleep is having a single clinician who understands all three categories, can evaluate interactions, and can adjust the plan as the clinical picture changes.

The framework for combining approaches is straightforward. Start with the evaluation to identify the drivers. Treat the primary psychiatric condition if one exists. Layer in a sleep-specific intervention if sleep does not improve with the primary treatment. Use the lowest-risk option first (supplements, behavioral strategies, non-dependency-forming prescriptions). Escalate only as needed. Monitor. Adjust. The goal is not to find the one perfect intervention. The goal is to build a treatment plan that addresses all the relevant factors and can be adjusted as those factors change.

For patients with PTSD-related sleep disruption that has not responded to conventional approaches, emerging therapies for trauma and PTSD including MDMA-assisted therapy are advancing through FDA review and may eventually offer additional options.

---

Frequently Asked Questions

What is the best medication for insomnia without dependency?

The dual orexin receptor antagonists (DORAs), suvorexant, lemborexant, and daridorexant, are FDA-approved for insomnia and have minimal abuse and dependency potential. Low-dose trazodone and low-dose doxepin are also widely used, non-dependency-forming options. The best choice depends on the specific sleep problem: difficulty falling asleep, difficulty staying asleep, or both.

Is trazodone safe for long-term use?

Trazodone has been used off-label for sleep for decades and is generally considered safe for long-term use at low doses (25 to 100 milligrams). It does not produce physiologic dependence or tolerance in most patients. Potential long-term concerns include persistent morning grogginess if the dose is too high and, rarely, priapism in men. Regular follow-up with the prescribing clinician is appropriate.

Do peptides for sleep actually work?

Some peptides have evidence for sleep-related effects, though the evidence base is smaller and less rigorous than for prescription medications. DSIP has the most direct evidence for sleep improvement, from small clinical trials showing improved sleep efficiency in chronic insomniacs. Epitalon and pinealon work through melatonin regulation rather than direct sedation. CJC-1295/ipamorelin improve sleep as a secondary effect of growth hormone optimization. None of these are FDA-approved sleep treatments, and all should be considered investigational.

What is the right dose of melatonin for sleep?

The physiologic dose of melatonin is 0.3 to 0.5 milligrams, which is far lower than what most commercial products contain. Higher doses (5 to 10 milligrams) do not produce better sleep and can cause next-morning grogginess and vivid dreams. Melatonin should be taken 30 to 60 minutes before the desired sleep onset. Timing matters as much as dose.

Does magnesium actually help with sleep?

Yes, particularly in individuals who are magnesium-deficient, which is common. Magnesium glycinate and magnesium L-threonate are the best-studied forms for sleep. A 2024 randomized controlled trial showed magnesium L-threonate improved insomnia severity scores compared to placebo. Typical effective doses are 200 to 400 milligrams of elemental magnesium from a well-absorbed form, taken before bed.

Can a psychiatrist prescribe sleep medications?

Yes. Psychiatrists are licensed physicians who can prescribe the full range of sleep medications, including controlled substances. Psychiatrists are also trained to evaluate the psychiatric conditions (anxiety, depression, PTSD, bipolar disorder) that commonly drive or worsen insomnia, which means they can treat the underlying cause alongside the sleep symptom rather than medicating the symptom alone.

Is CBD effective for sleep?

The evidence for CBD as a direct sleep aid is limited and inconsistent. Most of the evidence suggesting CBD helps sleep comes from anxiety studies, where reduced anxiety secondarily improved sleep. Controlled trials specifically for insomnia are lacking. CBD also has significant drug interaction potential through CYP enzyme inhibition, and product quality in the commercial market is inconsistent. It may help some patients but should not be considered a first-line sleep intervention.

What supplements can I take with prescription sleep medication?

Magnesium, glycine, and L-theanine are generally safe to combine with most prescription sleep medications, but this should always be discussed with the prescribing clinician. CBD has significant drug interaction potential and should be disclosed to any prescriber. High-dose melatonin alongside a prescription sleep medication can cause excessive sedation. The safest approach is to have one clinician coordinating both supplement and prescription use.

Are orexin receptor antagonists better than Z-drugs?

For chronic insomnia, yes, in most clinical scenarios. DORAs have lower dependency potential, less abuse potential, no rebound insomnia in most studies, and they preserve natural sleep architecture. Z-drugs remain useful for short-term or situational insomnia but are not recommended as first-line for chronic insomnia in current guidelines. DORAs represent the most significant advancement in prescription sleep pharmacology in recent years.

What is the difference between peptides and supplements for sleep?

Peptides are short chains of amino acids that act through specific receptor targets and are typically obtained through a prescribing clinician or compounding pharmacy. Supplements are vitamins, minerals, amino acids, or plant extracts available over the counter without a prescription. Peptides generally have more targeted mechanisms of action, while supplements tend to provide broader nutritional support. Both have smaller evidence bases than FDA-approved prescription medications. The evidence standard applied to both should be the same: what is the mechanism, what do the studies show, and is this the right fit for this patient.

How does a psychiatrist approach sleep differently from a sleep clinic?

A sleep clinic is typically focused on diagnosing and treating primary sleep disorders: sleep apnea, narcolepsy, restless legs syndrome, circadian rhythm disorders. A psychiatrist approaches sleep through the lens of the psychiatric conditions that frequently drive or worsen insomnia: anxiety, depression, PTSD, bipolar disorder, ADHD, substance use, and medication side effects. The two perspectives are complementary. Many patients benefit from both. A psychiatrist is particularly valuable when the sleep problem is intertwined with mood, anxiety, or medication management.

Can peptides be combined with SSRIs or other psychiatric medications?

Some peptides can be used alongside psychiatric medications, but this requires careful clinical oversight. The interaction profiles for most peptides are not as well-characterized as for prescription-to-prescription interactions, which is precisely why this combination should be managed by a clinician who understands both categories. A psychiatrist who understands both peptides and psychiatric medications can monitor for interactions, adjust dosing, and ensure the overall treatment plan is coherent rather than fragmented.

---

The Bottom Line

Sleep problems that persist despite basic sleep hygiene usually have a driver that sleep hygiene alone cannot address. Finding that driver, whether it is anxiety, depression, hormonal changes, medication effects, or something else, is the first step. Once the driver is identified, the treatment landscape includes prescription medications spanning multiple mechanism classes, peptides with early but genuine evidence for sleep modulation, and supplements that range from well-supported (magnesium, glycine) to popular but weakly evidenced (valerian, CBD).

When depression hasn’t improved after two or more antidepressants, sleep apnea is one of the first things I check. I cover the rest of that review on my treatment-resistant depression page.

The most important thing a psychiatrist brings to this landscape is not a prescription pad. It is the ability to look at all the pieces: the mood, the anxiety, the hormones, the medications, the substances, the sleep itself, and build a plan that addresses the actual picture rather than treating each symptom in isolation. That integrated approach is what distinguishes psychiatric sleep management from picking a supplement off a shelf.

---